Clinical trials: Vascular Conditions
Intracerebral Hemorrhage, Stroke
The Second Intensive Blood Pressure Reduction in Acute Cerebral Haemorrhage Trial
The purpose of this academic lead study is to determine if a treatment strategy of early intensive blood pressure (BP) lowering compared to conservative BP lowering policy in patients with elevated blood pressure within 6 hours…
- Conditions
- Intracerebral Hemorrhage, Stroke, Hypertension
- Trial name
- INTERACT2 (NCT00716079)
- Testing
- Blood pressure management policies
- Where
- 62 sites in United States, Argentina and 17 more
- Volunteers
- 2,839 people
- Sponsor
- The George Institute
Atrial Fibrillation, Thromboembolism
AMPLATZER™ LAA Occluder Post Approval Study (PAS)
The aim of this multicenter, non-randomized observational post-approval is to compile real world outcome data on the use of an AMPLATZER LAA Occluder in subjects with non-valvular atrial fibrillation (NVAF).
- Conditions
- Atrial Fibrillation, Thromboembolism, Stroke
- Trial name
- NCT02964208
- Testing
- AMPLATZER™ LAA Occluder
- Where
- 22 sites in Argentina, Belgium and 5 more
- Volunteers
- 520 people
- Sponsor
- Abbott Medical Devices
Angina Pectoris, Coronary Artery Disease
Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina
This study will evaluate the effect of ranolazine compared to placebo on the average weekly angina frequency in subjects with chronic stable angina and coronary artery disease (CAD) who have a history of type 2 diabetes mellitus…
- Conditions
- Angina Pectoris, Coronary Artery Disease, Type 2 Diabetes Mellitus
- Trial name
- TERISA (NCT01425359)
- Testing
- Ranolazine
- Where
- 135 sites in United States, Belarus and 12 more
- Volunteers
- 949 people
- Sponsor
- Gilead Sciences
End Stage Renal Disease, Thrombosis
Safety and Efficacy Study of AB023 (Xisomab 3G3) in End Stage Renal Disease Patients on Chronic Hemodialysis
This study evaluates the safety and efficacy of AB023 (xisomab 3G3) in patients with end stage renal disease on chronic hemodialysis. Two dose levels will be evaluated in two cohorts.
- Trial name
- NCT03612856
- Testing
- AB023- Dose 1, AB023-Dose 2
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Aronora, Inc.
Multiple Myeloma, Diarrhea
A Study of Colesevelam for Lenalidomide-Associated Diarrhea
The purpose of this study is to test the safety of colesevelam and find out what effects, if any, colesevelam has on lenalidomide associated diarrhea in participants with multiple myeloma on lenalidomide maintenance.
- Trial name
- NCT03767257
- Testing
- Colesevelam Pill
- Where
- 7 sites in United States
- Volunteers
- 25 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Left Sided Heart Failure, Left Ventricular Assist Device
Ventricular Assist Device Anti-Factor Xa (VAD ANTIX) Monitoring Study: a Prospective Randomized Feasibility Trial
This study evaluates two different methods for monitoring a patient's anti-clotting [heparin] therapy after they receive a heart pump implant [left ventricular assist device -LVAD].
- Conditions
- Left Sided Heart Failure, Left Ventricular Assist Device, Anticoagulant Therapy, Gastro Intestinal Bleeding
- Trial name
- VAD-ANTIX (NCT03143569)
- Testing
- aPTT guided heparin management, Anti-factor Xa guided heparin management
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Washington University School of Medicine
Obesity
Cardiometabolic Disease and Pulmonary Hypertension
This study will investigate if metformin can help people with obesity and high pressures inside their lung blood vessels. Metformin is approved by the U.S.
- Trial name
- NCT03349775
- Testing
- Metformin
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Massachusetts General Hospital
Bone Sarcoma, Femur Fracture
Dalteparin in Preventing DVT in Participants With Cancer
This trial studies how well dalteparin works in preventing deep vein thrombosis (DVT) (blood clots) in participants with cancer. Dalteparin is a blood thinner that can treat blood clots and may prevent them from forming.
- Conditions
- Bone Sarcoma, Femur Fracture, Lymphoma, Metastatic Neoplasm
- Trial name
- NCT00525057
- Testing
- Dalteparin
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- M.D. Anderson Cancer Center
Cardiovascular Diseases, Depression
Omega-3 Fatty Acids to Improve Depression and Reduce Cardiovascular Risk Factors
This study will determine the effects of omega-3 fatty acid (FA) augmentation of sertraline on depression and cardiac endpoints after myocardial infarction (MI).
- Conditions
- Cardiovascular Diseases, Depression, Heart Diseases, Myocardial Infarction
- Trial name
- NCT00116857
- Testing
- Sertraline/omega-3, Sertraline/Corn Oil
- Where
- United States
- Volunteers
- 122 people
- Sponsor
- Washington University School of Medicine
Pulmonary Arterial Hypertension
Safety, Pharmacokinetics and Efficacy Study of QCC374 in PAH Patients
This was a non-confirmatory, randomized, placebo controlled, subject and investigator blinded study of QCC374 in PAH subjects. The study was planned to have 2 Parts: Part 1, an initial safety cohort with a 0.03 mg bid starting…
- Trial name
- NCT02927366
- Testing
- QCC374
- Where
- 5 sites in United States, Germany and 2 more
- Volunteers
- 8 people
- Sponsor
- Novartis Pharmaceuticals
Relapsed and Bortezomib Refractory Multiple Myeloma, Refractory Multiple Myeloma
Efficacy of Panobinostat in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma
This study is designed to assess the effectiveness of the combination of Panobinostat plus Bortezomib and Dexamethasone in patients with relapsed and bortezomib refractory Multiple Myeloma.
- Conditions
- Relapsed and Bortezomib Refractory Multiple Myeloma, Refractory Multiple Myeloma, Multiple Myeloma in Relapse
- Trial name
- MACS1271 (NCT01083602)
- Testing
- panobinostat, bortezomib, dexamethasone
- Where
- 13 sites in United States
- Volunteers
- 55 people
- Sponsor
- Novartis Pharmaceuticals
Myocardial Infarction, Stroke
Women's Health Initiative Strong and Healthy Study
The WHISH trial applies state-of-the science behavioral principles and currently available technologies to deliver a physical activity intervention without face-to-face contact to ~25,000 older U.S. women expected to consent.
- Conditions
- Myocardial Infarction, Stroke, Cardiovascular Mortality, Hip Fractures
- Trial name
- WHISH (NCT02425345)
- Testing
- Physical Activity
- Volunteers
- 49,331 people, healthy volunteers welcome
- Sponsor
- Fred Hutchinson Cancer Center
Cerebral Palsy, Hypoxic-Ischemic Encephalopathy
Therapeutic Intervention Supporting Development From NICU to 6 Months for Infants Post Hypoxic-Ischemic Encephalopathy
The purpose of this study is to evaluate the feasibility and begin to evaluate the effect of a sensorimotor intervention (SMI) provided in the first 6 months of life for infants with hypoxic-ischemic encephalopathy.
- Trial name
- NCT05130528
- Testing
- Sensorimotor Intervention
- Where
- 2 sites in United States
- Volunteers
- 11 people
- Sponsor
- University of Southern California
Acute Coronary Syndrome
Plaque Regression and Progenitor Cell Mobilization With Intensive Lipid Elimination Regimen (PREMIER), Phase I
The purpose of this randomized, multi-site, clinical trial is to determine whether intensive therapy consisting of cholesterol-lowering statin drugs plus apheresis to cleanse the blood of low-density lipoprotein (LDL) cholesterol…
- Trial name
- PREMIER (NCT01004406)
- Testing
- intensive LDL-lowering therapy, standard statin monotherapy
- Where
- 2 sites in United States
- Volunteers
- 59 people
- Sponsor
- VA Office of Research and Development
Ischemic Stroke
Japan Statin Treatment Against Recurrent Stroke (J-STARS)
Although hyperlipidemia is not always the risk factor of stroke, inhibition of 3-hydroxy-3-methylglutaryl-coenzyme A(HMG-CoA) reductase can decrease the incidence of stroke in the patient with ischemic heart disease.
- Trial name
- NCT00221104
- Testing
- Pravastatin
- Where
- Japan
- Volunteers
- 1,578 people
- Sponsor
- Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
Chronic Spontaneous Urticaria
This Was a Dose-finding Study to Evaluate Efficacy and Safety of LOU064 in Patients With CSU Inadequately Controlled by H1-antihistamines
This was a multicenter, randomized, double-blind and placebo-controlled phase 2b dose-finding study to assess the efficacy and safety of LOU064 in adults chronic spontaneous urticaria (CSU) patients inadequately controlled by…
- Trial name
- NCT03926611
- Testing
- LOU064 Arm 1, LOU064 Arm 2, LOU064 Arm 3
- Where
- 82 sites in United States, Argentina and 15 more
- Volunteers
- 311 people
- Sponsor
- Novartis Pharmaceuticals
Acute Kidney Injury, Fluid Overload
Restrictive Versus Liberal Rate of Extracorporeal Volume Removal Evaluation in Acute Kidney Injury
Critically ill patients with acute kidney injury and fluid overload who are frequently treated by fluid removal during dialysis are at an increased risk of complications and death.
- Conditions
- Acute Kidney Injury, Fluid Overload, Hypotension, Dialysis; Complications
- Trial name
- RELIEVE-AKI (NCT05306964)
- Testing
- Restrictive UFnet Rate Strategy, Liberal UFnet Rate Strategy
- Where
- 2 sites in United States
- Volunteers
- 99 people
- Sponsor
- University of Pittsburgh
Acute Myocardial Infarction
ClearWay Rx Readmission Registry
The purpose of this registry is to determine if delivery of weight adjusted, in a large dose with either Abcixmab or Eptifibitide through the ClearWay™ RX, in patients admitted for primary coronary intervention lowers readmission…
- Trial name
- ClearWay (NCT01673893)
- Testing
- ClearWay™ Rx catheter
- Where
- United States
- Volunteers
- 59 people
- Sponsor
- Cardiovascular Institute of the South Clinical Research Corporation
Multiple Myeloma
A Study of Venetoclax in Combination With Pomalidomide and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma
This was an open-label, multicenter study designed to evaluate the safety and preliminary efficacy of venetoclax combined with pomalidomide and dexamethasone in participants with relapsed or refractory (R/R) multiple myeloma (MM)…
- Trial name
- NCT03567616
- Testing
- Venetoclax, Pomalidomide, Dexamethasone
- Where
- 11 sites in United States, Spain and 1 more
- Volunteers
- 8 people
- Sponsor
- AbbVie
Venous Leg Ulcer
Effect of VarIthena on Wound Healing in Venous Leg Ulcers (VLU)
A 12 month, multicenter, open-label registry to observe chronic venous insufficiency resulting in VLU treated with Varithena.
- Trial name
- VIEW-VLU (NCT03257254)
- Testing
- Varithena
- Where
- 14 sites in United States, Canada
- Volunteers
- 76 people
- Sponsor
- Boston Scientific Corporation
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.